Johnson & Johnson said on Thursday that a real-world study showed its single-shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.
The study, sponsored by the vaccine developer, was conducted between Jan. 1 and Sept. 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.
J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech’s as well as Moderna .
No waning of protection was found for ICU admissions for all the three vaccines, J&J said. The company said the study was carried out by collecting claims and laboratory data covering 168 million people.
- Hundreds line up in China hospital as respiratory illness surges, video shows
- After husband and wife die of cancer, Ont. hospital announces staggering $20M donation in their name
- Pharmacare bill unlikely to pass by end of year despite NDP agreement: Gould
- Stigma around PTSD still exists despite ‘shock’ around Ontario police officer’s death